A Study in Adult and Pediatric Patients With Cystic Fibrosis
Completed
Merck Sharp & Dohme Corp.
Phase 1/Phase 2
The purpose of this ascending dose group study is to assess the safety, tolerability, and
effects of multiple dose levels of INS37217 and placebo followed by five days twice daily
treatment with maximum tolerated dose administered by inhalation via the Pari LC Star
nebulizer in adult and pediatric patients with cystic fibrosis
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
Completed
Cystic Fibrosis Foundation
Phase 2
The purpose of this study is to assess the safety and effectiveness of multiple dosages of
INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis
(CF) lung disease. Study drug will be administered through a nebulizer (a device that
delivers medication as a mist by breathing it in).
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
Completed
Cystic Fibrosis Foundation Therapeutics
Phase 2
The purpose of this study is to assess the safety and effectiveness of multiple dosages of
INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis
(CF) lung disease. Study drug will be administered through a nebulizer (a device that
delivers medication as a mist by breathing it in).
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
Completed
Merck Sharp & Dohme Corp.
Phase 2
The purpose of this study is to assess the safety and effectiveness of multiple dosages of
INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis
(CF) lung disease. Study drug will be administered through a nebulizer (a device that
delivers medication as a mist by breathing it in).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
